

s 2022 0056

The invention relates to medicine, in particular to molecular genetics, gynecology and oncology, and can be used for predicting the course of stage I-II endometrial cancer.

Summary of the invention consists in that it is analyzed the isolated genomic DNA using the chain polymerization reaction, where is established the presence of MLH1 epimutation, if its presence is determined, an unfavorable course of endometrial cancer is predicted, and if the presence of mutation is not established, a favorable course of the disease is predicted.

Claims: 1